SEC Form 4 · accession 0000899243-17-003646
NEKTAR THERAPEUTICS · NKTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Howard W Robin
Officer — President & CEO · Director
Period of report
Feb 8, 2017
Accepted (ET)
Feb 10, 2017 · 8:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000906709
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 8, 2017 | M | 87,500 | $4.65 | A | 265,408 | D | |
| Common StockF1,F2 | Feb 8, 2017 | S | 87,500 | $13.04 | D | 177,908 | D | |
| Common Stock | holding | — | — | — | 410 | I | by spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $4.65 | Feb 8, 2017 | M | 87,500 | D | Feb 23, 2013 | Feb 22, 2017 | Common Stock | 87,500 | 0 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan (the "Expiring Option Plan") adopted by Mr. Robin in May 2015 and reported on a Form 8-K filed by Nektar Therapeutics on July 16, 2015. The Expiring Option Plan provides for the exercise and same-day sale of expiring stock options held by Mr. Robin on a monthly pro-rata basis on pre-specified dates over the six month period prior to stock option expiration.
- F2This transaction was executed in multiple trades at prices ranging from $12.71 to $13.22. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.